Document is current
Any future updates will be listed below
-
Authors
Yetkin-Arik, B. https://orcid.org/0000-0002-6986-0004
Jansen, S. A. https://orcid.org/0000-0002-1225-9963
Varderidou-Minasian, S. https://orcid.org/0000-0001-7879-4291
Westendorp, B. https://orcid.org/0000-0003-1043-3638
Skarp, K.-P.
Altelaar, M. https://orcid.org/0000-0001-5093-5945
Lindemans, C. A. https://orcid.org/0000-0002-3984-5620
Lorenowicz, M. J. https://orcid.org/0000-0001-8420-2029
-
Funding
Funding for this research was provided by:
Kika (363)
Alexandre Suerman Stipend
European Proteomics Infrastructure Consortium providing access (823839)
NWO funded National Road Map for Large-scale Infrastructures program X-Omics (184.034.019)
- License Information
-
More Information
Article History
Received: 6 October 2023
Accepted: 20 April 2024
First Online: 29 April 2024
Declarations
:
: Organoids used in this study had previously been generated from biopsies obtained from individuals initially suspected of coeliac disease, but declared free of pathology, within the institutional review board study protocol METC 10-402/K approved first on 6 June 2011 and thereafter renewed approval on 5 December 2019. All samples had been obtained after written informed consent, were biobanked, and the current use falls under their permission. MSCs were isolated from third-party non-HLA-matched healthy bone marrow donors as approved by the Dutch Central Committee on Research Involving Human Subjects (CCMO, Biobanking bone marrow for MSC expansion, NL41015.041.12; approved on 17 January 2013) and all samples were obtained with written informed consent from the bone marrow donor or parent/legal guardian of the donor.
: All authors approved the publication for this manuscript.
: The authors declare no conflict of interest.
